Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly non-alcoholic fatty liver disease, is the most prevalent chronic liver disorder globally and is tightly l
This is a narrative review synthesizing mechanistic pathways and existing evidence rather than presenting original clinical data or trial results, raising questions about the menopause-obesity-MASH axis rather than answering them with new evidence.